

Table SI. Clinical characteristics of patients with acute heart failure recruited for the study

	All patients (n=84)	Patients with itch (n=14)	Patients without itch (n=70)	p-value
Clinical data				
Sex (males), n (%)	63 (75)	11 (79)	52 (74)	ns
Age, years, mean (SD)	66±13	62±14	67±12	ns
LVEF, %, mean (SD)	36±13	40±16	36±13	ns
NYHA (before hospitalization), n (%)				
I	0	0	0	
II	0	0	0	
III	54 (64)	5 (36)	48 (69)	
IV	30 (36)	9 (64)	22 (31)	0.020
Comorbidities, n (%)				
AF	40 (48)	9 (64)	31 (44)	ns
Hypertension	60 (71)	10 (71)	50 (71)	ns
DM type 2	31 (37)	6 (43)	25 (36)	ns
COPD	10 (12)	3 (21)	7 (10)	ns
CKD	26 (31)	4 (29)	22 (31)	ns
Thyroid diseases	11 (13)	2 (15)	9 (14)	ns
Medications before hospitalization, n (%)				
ACEI	66 (79)	10 (71)	56 (81)	ns
Aldosterone antagonists	36 (43)	8 (67)	28 (40)	ns
ARB	8 (10)	3 (2)	5 (7)	ns
ASA	32 (38)	5 (36)	27 (39)	ns
Beta-receptor blockers	74 (88)	14 (100)	60 (87)	ns
Calcium channel blockers	8 (10)	0 (0)	8 (11)	ns
Loop diuretics	51 (61)	9 (64)	42 (60)	ns
NOAC	6 (7)	3 (21)	3 (4)	0.023
Statins	56 (67)	10 (71)	46 (67)	ns
Thiazide diuretics	16 (19)	4 (29)	12 (17)	ns
Warfarin	16 (19)	4 (29)	12 (17)	ns
Medications during hospitalization, n (%)				
Loop diuretics, median (IQR)	84 (100)	14 (100)	70 (100)	ns
Inotropic agents, median (IQR)	13 (15)	5 (36)	8 (11)	0.022
Vasodilators	41 (49)	8 (57)	33 (47)	ns
Laboratory results				
NTpro BNP, median (IQR)	5,112 (3,081–126,901)	3,612 (3,058–6,272)	5,244 (3,113–13,503)	ns
Troponin, median (IQR)	0.1 (0.04–0.46)	0.08 (0.04–0.15)	0.1 (0.04–0.62)	ns
Hb, g/dl, mean±SD	13.2±1.7	12.4±1.8	13.4±1.7	ns
Ht, %, mean±SD	40±5	38±5	40±5	ns
CRP, mg/l, median (IQR)	13.2 (6.4–46.4)	13.2 (2.2–52.6)	13.2 (6.9–46.4)	ns
Creatinine, mean±SD	1.4±0.6	1.5±1.0	1.4±0.5	ns
AST, median (IQR)	32 (26–50)	36 (26–50)	32 (26–50)	ns
ALT, median (IQR)	38 (25–68)	29 (18–52)	42 (26–70)	ns
Bilirubin, median (IQR)	1.4 (0.9–1.8)	1.8 (1.2–3.4)	1.2 (0.8–1.7)	0.043
Glucose, mean±SD	135±40	125±32	137±41	ns
Na+, mean±SD	138±6	136±5	138±6	ns
K+, mean±SD	4.1±0.6	3.9±0.5	4.2±0.6	Ns

ACEI: angiotensin-converting-enzyme inhibitor; AF: atrial fibrillation; ALT: alanine transaminase; ARB: angiotensin II receptor blockers; AST: aspartate transaminase; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; CRP: c-reactive protein; DM: diabetes mellitus; Hb: hemoglobin; Ht: hematocrit; K+: potassium; LVEF: left ventricular ejection fraction; Na+: sodium; NOAC: non-vitamin K oral anticoagulants; NTproBNP: N-terminal prohormone of brain natriuretic peptide; ns: not significant; NYHA: New York Heart Association; IQR: interquartile range.